GOLDEN, Colo. — March 27, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced plans to present their latest research results at the World Vaccine Congress on April 5, in Washington DC at the Renaissance Washington DC Downtown Hotel. The presentation, entitled Expanding Vaccine Effectiveness with Needle-free Delivery, will be presented by Dr. Erin Spiegel, Director of Scientific Affairs at PharmaJet, Inc.
Immunotherapy using novel pharmaceuticals has led to new emerging vaccines and therapeutics, based on platforms including DNA, RNA, antibodies, personalized medicine and others. For these nucleic acid-based vaccines to work, the vaccine must get directly into the cells, necessitating an improved delivery method. Multiple studies have shown that the PharmaJet Needle-free Injectors augment vaccine response, possibly by increased dispersion of injectate or through tissue disruption, enabling a more efficient uptake of vaccine and increased immunogenicity. These superior results have been replicated in several DNA and RNA vaccine clinical trials for zika virus, cancer, smallpox and rabies. Collaborators including the NIH, Invectys, Vaccibody, CureVac and others are using this technology to move from pre-clinical studies into human trials.
“We now have over 40 novel pharmaceuticals, including DNA and RNA vaccines and therapeutics, using our devices in pre-clinical and clinical studies worldwide,” said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc. “The data has been overwhelmingly positive for clinical efficacy using our devices1.”
Refer to Instructions for Use to ensure safe injections and to review risks.
1Data on file